Alterity Therapeutics Files 6-K, Incorporates into Registrations
Ticker: PRNAF · Form: 6-K · Filed: Mar 14, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Mar 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing-update, registration-statement, substantial-holder
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K, incorporating into existing S-8/F-3 filings. Exhibit 99.1 is a substantial holder notice.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on March 14, 2025, to report its activities for the month of March 2025. This filing incorporates by reference information into several of its existing Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, which details becoming a substantial holder.
Why It Matters
This filing serves to update SEC filings and incorporate new information, potentially impacting investors' understanding of the company's ongoing registration and disclosure obligations.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previous information into existing registration statements and includes a notice about a substantial holder, not indicating new material financial or operational changes.
Key Players & Entities
- ALTERITY THERAPEUTICS LTD (company) — Filer
- PRANA BIOTECHNOLOGY LTD (company) — Former Company Name
- Form S-8 (document) — Incorporated by reference into
- Form F-3 (document) — Incorporated by reference into
- Exhibit 99.1 (document) — Included in filing
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K is filed for the month of March 2025 and is being incorporated by reference into Alterity Therapeutics' existing Registration Statements on Form S-8 and Form F-3.
What specific exhibit is included with this filing?
Exhibit 99.1, titled 'Becoming a substantial holder', is submitted with this Form 6-K.
What is the company's principal executive office address?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics file annual reports under Form 20-F or Form 40-F?
Yes, the registrant indicates it files annual reports under cover of Form 20-F.
What was the former name of Alterity Therapeutics Ltd?
The former name of Alterity Therapeutics Ltd was PRANA BIOTECHNOLOGY LTD, with a date of name change on January 5, 2001.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 14, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).